Back to Previous Page
New SearchHide Search
Manufacturers of innovator and biosimilar medicines should have equal opportunities to secure treatment volumes based on the overall value of the medicine for patients and the health care systems.
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.
You are here
This site is intended for a global audience